BenevolentAI achieves second major collaboration milestone w

/PRNewswire/ -- BenevolentAI, a leading clinical-stage AI drug discovery company, announced that AstraZeneca has added a novel target for idiopathic pulmonary...

Related Keywords

New York , United States , London , City Of , United Kingdom , Prnewswire Benevolent , Anne Phelan , Eli Lilly , Maria Belvisi , Partnership Alliance , Astrazeneca , Head Of Research , Early Development , Benevolent Platform , Chief Scientific Officer , Idiopathic Pulmonary Fibrosis , Scrip Awards , Best Partnership Alliance , Benevolentai ,